Valuation: Fennec Pharmaceuticals Inc.

Market Cap 383M 334M 314M 287M 538M 36.57B 538M 3.77B 1.46B 18.68B 1.44B 1.41B 60.21B P/E 2026 *
36.4x
P/E 2027 * 11x
Enterprise Value 383M 334M 314M 287M 538M 36.57B 538M 3.77B 1.46B 18.68B 1.44B 1.41B 60.21B EV / Sales 2026 *
5.27x
EV / Sales 2027 * 3.71x
Free-Float
80.6%
Yield 2026 *
-
Yield 2027 * -
1 week-12.28%
Current month-11.76%
1 month-3.16%
3 months+18.20%
6 months+48.66%
Current year+41.51%
1 week 14.72
Extreme 14.72
15.08
1 month 14.53
Extreme 14.53
17.42
Current year 7.59
Extreme 7.59
17.64
1 year 7.59
Extreme 7.59
17.64
3 years 5.65
Extreme 5.65
17.64
5 years 4.95
Extreme 4.95
17.64
10 years 0
Extreme 0
18.86
Manager TitleAgeSince
Chief Executive Officer 64 15/08/2024
Director of Finance/CFO 51 05/01/2010
Chief Tech/Sci/R&D Officer 51 27/10/2024
Director TitleAgeSince
Director/Board Member 72 24/08/2011
Chairman 69 08/12/2015
Director/Board Member 70 09/08/2016
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-12.28% - - 383M
+0.36%+2.68%+54.52%+111.89% 1,038B
-0.50%+0.32%+53.87%+67.01% 649B
+0.61%+1.17%+19.56%+74.24% 467B
-0.19%+0.97%+34.30%+45.99% 355B
+0.28%+2.30%+18.47%+26.67% 269B
+0.89%+4.59%+10.19%+14.72% 260B
+3.56%+8.71%+42.79%+52.55% 213B
-0.46%-6.20%-32.46%-59.65% 176B
+1.41%+3.98%+35.23%+102.80% 187B
Average +0.61%+1.04%+26.27%+48.47% 401.68B
Weighted average by Cap. +0.42%+1.47%+36.09%+66.82%

Financials

2026 *2027 *
Net sales 72.56M 63.41M 59.6M 54.39M 102M 6.94B 102M 715M 276M 3.54B 273M 267M 11.42B 103M 90.11M 84.69M 77.28M 145M 9.86B 145M 1.02B 392M 5.03B 387M 379M 16.23B
Net income 10.48M 9.16M 8.61M 7.85M 14.74M 1B 14.74M 103M 39.86M 512M 39.35M 38.49M 1.65B 35.13M 30.7M 28.85M 26.33M 49.42M 3.36B 49.43M 346M 134M 1.71B 132M 129M 5.53B
Net Debt - -
Logo Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Employees
35
Date Price Change Volume
21/09/26 CA$15.00 0.00% 209
18/09/26 CA$15.00 -0.53% 112
17/09/26 CA$15.08 +2.45% 100
16/09/26 CA$14.72 +1.31% 680
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
10.91USD
Average target price
17.67USD
Spread / Average Target
+61.93%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!